184 ( 620 % , 95 % CI 562-675 ) patients in the cetuximab group achieved an objective response compared with 171 ( 580 % , 521-637 ) in the bevacizumab group ( odds ratio 118 , 95 % CI 085-164 ; p = 018 ) .